Table of Contents
- 01Introduction
- 02Where the Job Comes From
- 03What Lands on a Disclosure Specialist's Desk
- 04The Deadlines That Drive the Calendar
- 05Redaction: Protecting Patients and Trade Secrets
- 06Who Does This Work and How They Get There
- 07Where the Role Sits on a Team
- 08Why This Work Is Getting More Attention
- 09Tools and Systems the Work Runs On
- 10Conclusion
Introduction
Somewhere between the last patient visit and the published results sits a stack of deadlines that most people outside clinical operations never think about. A trial has to be registered before it enrolls its first patient. Its results have to be posted, in a specific structured format, within a set window after the trial ends. A plain-language summary has to be written for the people who were actually in the study, not for regulators. And before any of that goes public, someone has to decide exactly what can be redacted and what cannot. That work has a name: clinical trial disclosure, and the people who do it sit at an unusual intersection of clinical operations, regulatory affairs, medical writing and law.
Where the Job Comes From
Trial disclosure is not a courtesy sponsors extend to the public; it is a legal obligation with real deadlines attached. In the United States, the Food and Drug Administration Amendments Act of 2007, usually shortened to FDAAA 801, requires sponsors of applicable clinical trials to register them on ClinicalTrials.gov and post summary results, generally within a year of the trial's primary completion date, with the submission format and timing governed by regulations at 42 CFR Part 11. In the European Union, the Clinical Trials Regulation requires sponsors to submit trial information and results through the Clinical Trials Information System, CTIS, including a layperson summary written in terms a non-scientist participant could understand. The European Medicines Agency's longstanding policy on proactive publication of clinical data adds another layer, requiring redacted clinical study reports to be made public once a marketing authorization decision has been issued. None of this is optional, and none of it waits for a product launch to matter; a trial that never leads to an approved product still has to be disclosed. Discontinued programs and negative trials carry the same registration and results-posting obligations as successful ones, which is part of the point: the regulatory framework exists precisely to prevent a sponsor from quietly shelving an unfavorable result rather than reporting it alongside the trials that worked.
87 open now
Clinical operations roles
Clinical Operations Associate DirectorBridgeBioRemote, US$191K
Senior Clinical Trials Systems ManagerNateraRemote, US$142K
Associate Technical Liaison, Clinical TrialsLabcorpIndianapolis, IN · Hybrid
Study Start Up Manager - IQVIA BiotechIQVIADurham, NC$58K–$216K
What Lands on a Disclosure Specialist's Desk
Day to day, the work is less about science and more about accuracy, formatting and timing. A disclosure specialist maintains the registry record for every active trial, updating it whenever the protocol changes, enrollment status shifts, or a site is added or closed, since an out-of-date registry entry is itself a compliance finding waiting to happen. When a trial completes, the specialist pulls structured results data, usually working from the statistical analysis plan and the clinical study report, and maps it into the registry's required results tables, a process that has far less room for interpretation than most clinical documents and far more room for a single mismatched number to trigger a query. Writing the layperson summary is its own discipline entirely, translating endpoints, adverse event rates and statistical outcomes into language a patient with no scientific background can actually follow, without oversimplifying the findings or implying a conclusion the data does not support.
The Deadlines That Drive the Calendar
What makes disclosure work distinct from most regulatory functions is how unforgiving the clock is. Results posting deadlines are measured in months from a fixed date, not from whenever the team gets around to it, and missing one can mean a noncompliance notice, a posted violation on the public registry, or in the US a referral that can carry civil monetary penalties. A disclosure specialist typically manages a portfolio of trials at different stages simultaneously, each with its own primary completion date and its own countdown, which means the job runs on a tracking system as much as it runs on writing skill. Extensions exist for legitimate reasons, such as an ongoing trial for the same product where early disclosure could compromise the science, but requesting one requires its own documentation and justification, not a quiet assumption that nobody is watching.
Redaction: Protecting Patients and Trade Secrets
Before a clinical study report or a protocol becomes public, it has to be redacted, and that is where the job gets genuinely difficult. Two categories of information typically come out: personal data that could identify a trial participant, and commercially confidential information such as manufacturing details, proprietary analytical methods, or competitive strategy that a sponsor has a legitimate interest in protecting. Deciding where that line falls is not mechanical. Redact too little and a company exposes trade secrets or participant privacy; redact too much and a regulator can reject the submission as insufficiently transparent, since agencies increasingly scrutinize redaction requests for overreach. Disclosure specialists typically work from an anonymization and redaction plan agreed with regulatory and legal colleagues well before the document is finalized, so the redaction logic is defensible rather than improvised against a deadline.
The anonymization and redaction plan itself has become a document worth real investment. It sets out, section by section, what categories of information in a clinical study report are expected to require redaction, what the basis for each redaction is, and how participant-level data will be handled differently from aggregate findings. Agencies reviewing a redacted report increasingly expect the sponsor to justify each redaction individually rather than submit a document with broad sections blacked out on a blanket assumption of confidentiality. A disclosure specialist who has built the plan early, alongside the clinical study report itself rather than after it, tends to move through this stage far faster than one starting the redaction conversation from scratch once the deadline is already close.
Who Does This Work and How They Get There
Few people start their career aiming at disclosure. Most arrive from adjacent roles: clinical research coordinators and clinical research associates who developed an eye for registry accuracy, medical writers who moved from authoring clinical study reports to managing their public release, and regulatory operations specialists who already understood submission systems and simply extended that fluency to CTIS and ClinicalTrials.gov. What the role actually rewards is a combination that is harder to find than it sounds: comfort with structured data and tracking systems, writing skill precise enough to survive a compliance audit, and enough clinical literacy to know when a summary has quietly misrepresented a finding. Formal credentials specific to disclosure are limited, but familiarity with Good Clinical Practice, clinical trial registries and plain-language writing principles is the baseline most hiring managers look for.
Where the Role Sits on a Team
At larger sponsors, disclosure sits inside a dedicated transparency or disclosure function, often reporting into clinical operations or regulatory affairs rather than medical writing directly, though all three groups stay in close contact on every trial. Smaller sponsors and many CROs fold the work into a broader regulatory operations or medical writing role, which means a disclosure specialist there wears several hats and has to protect disclosure deadlines against competing submission deadlines that can look more urgent in the moment. Either structure works, but the deadlines do not bend for either one.
Why This Work Is Getting More Attention
Public and academic scrutiny of trial transparency has grown steadily, with independent audits of registry compliance regularly surfacing late or missing results postings across the industry, and regulators have shown more willingness to flag noncompliance publicly rather than handle it quietly. The EU's shift to CTIS as the single point of entry for trial applications and results across member states has also raised the operational bar, since the system enforces structured data requirements that a spreadsheet-based process cannot easily satisfy. For sponsors running global trial portfolios, disclosure is no longer a task that can be handled reactively a few weeks before a deadline; it increasingly requires dedicated headcount and systems built specifically for it.
Tools and Systems the Work Runs On
Disclosure work has also become more technical than its reputation suggests. Most sponsors of any scale now run dedicated clinical trial registration and disclosure software, often integrated with or sitting alongside a regulatory information management system, to track every trial's registration status, outstanding results postings and redaction milestones in one place rather than in a spreadsheet maintained by one person's institutional memory. That tooling matters because a missed internal deadline is just as costly as a missed regulatory one; by the time a results posting is actually late in a public registry, there is no good way to make it look otherwise. Disclosure specialists who are comfortable configuring and troubleshooting these systems, not just using them, tend to become the people a regulatory operations team relies on most, since the tooling itself has to be adapted every time a registry changes its submission format or a region updates its reporting requirements.
Conclusion
Clinical trial disclosure rarely gets the attention that trial design or regulatory strategy does, but it is one of the few places in a clinical trial's lifecycle where the public actually sees the work. Getting it right takes a specific mix of regulatory fluency, writing discipline and an unforgiving relationship with deadlines, which is exactly why sponsors are increasingly building dedicated roles around it rather than treating it as a side task for whoever has time.

Regulatory & Quality. REWIRED.
New roles. Real pay. Your next move.
- Hand-picked roles, every week.
- The newest company pages.
- One article worth your time.
Free. Thursday mornings. One-click unsubscribe.
Find your next regulatory or quality role
Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.





